SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors speculate on its AI-driven infrastructure and potential for long-term utility growth within the Base ecosystem. The community remains focused on accumulation and holding, viewing recent market dips as entry points for a project they believe is heavily undervalued relative to its sector peers.

Microchip Technology, Inc. engages in the provision of semiconductor products. It operates through the Semiconductor Products and Technology Licensing segments. The Semiconductor Products segment is involved in designing, developing, manufacturing, and marketing microcontrollers, development tools and analog, interface, mixed signal, connectivity devices, and timing products. The Technology Licensing segment offers license fees and royalties associated with technology licenses for the use of SuperFlash embedded flash and Smartbits one-time programmable technologies. The company was founded on February 14, 1989 and is headquartered in Chandler, AZ.

Microchip Technology, Inc.

Microchip Technology is trending as the community debates its recovery potential and valuation amid a challenging semiconductor cycle. Investors are closely monitoring its operational rebound following a recent cyberattack while weighing its long-term positioning in industrial, automotive, and data center markets.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors navigate aggressive swings driven by a mix of geopolitical tensions, central bank policy concerns, and sector-specific earnings. Community sentiment is deeply polarized, with active debates centered on whether the current semiconductor rally is a sustainable AI-driven shift or a speculative bubble vulnerable to a sharp correction.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Community sentiment for XRP remains heavily influenced by the anticipated passage of the CLARITY Act, which investors believe will provide regulatory certainty and facilitate broader institutional integration for the token. Discussions are currently polarized between bulls who are actively accumulating on dips in expectation of a major price rally and skeptics who remain cautious due to historical price volatility and market structure concerns.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest its latest earnings report, which featured raised full-year guidance and strong AI-driven demand, despite short-term concerns regarding export controls and semiconductor market volatility. Community members are actively debating the stock's long-term dominance in lithography against broader macro risks, with many traders closely monitoring the impact of AI infrastructure spending on equipment demand.

Direxion Shares ETF Trust - Direxion Daily Gold Miners Index Bull 2X ETF

Direxion Daily Gold Miners Index Bull 2X Shares

NUGT is experiencing intense volatility as traders debate whether the stock is primed for a parabolic breakout fueled by macro economic uncertainty and central bank gold accumulation or if it is currently overbought and facing a significant correction. Community discussion is heavily divided between long-term bulls positioning for a potential commodity supercycle and traders capitalizing on daily swings and technical indicators signaling a possible reversal.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos Holdings, Inc. (LDOS) is drawing investor attention as it secures major defense and logistics contracts, including a notable multibillion-dollar airport security equipment sustainment deal. While the stock has faced volatility amid market concerns regarding government spending efficiency, the community remains divided, with bulls highlighting its robust backlog and role in critical defense modernization, while bears express caution over sector-wide downward trends.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors weigh the stock's recent volatility against its aggressive expansion into crypto trading and AI-integrated wealth management tools. The community remains divided, with many traders discussing the firm's system reliability and restrictions, while others view the pullback as a buying opportunity given the company's strong long-term client asset growth.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch progress of Yartemlea, supported by the recent assignment of a permanent reimbursement J-code that simplifies billing and hospital adoption. Community discussions center on the company's long-term potential, with bullish sentiment driven by the drug's first-in-class status for TA-TMA and anticipation of upcoming European regulatory catalysts.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is gaining momentum as investors eye the company's rare earth magnet production capacity and its strategic positioning within the domestic critical minerals supply chain. Community discussion centers on the stock's low-float structure and potential for volatility, with many users tracking its resilience compared to the broader mining sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...

<ul class="summary-bullets"><li>The data were presented at the American Urological Association (AUA) 2026 Annual Meeting.</li><li>Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug.</li><li>If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.</li></ul> Shares of Candel Therapeutics Inc. (CADL) rose 3% in after-hours trading on Friday following the release of extended follow-up data from its pivotal late-stage trial of CAN-2409 in intermediate- to high-risk localized prostate cancer.The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo in the intention-to-treat population. In the intermediate-risk subgroup — which made up 85% of the 745-patient trial — the benefit was even stronger, with a 41% reduction in risk of recurrence, along with notable improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, the firm said.The data, which reinforces the potential of the drug to reduce the risk of tumor recurrence, were presented at the American Urological Association (AUA) 2026 Annual Meeting.<h2 class="st-heading-2">Plan Ahead</h2>Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug. If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.<h2 class="st-heading-2">What Did Phase 3 Results Show?</h2>In December 2024, Candel reported positive late-stage results for CAN-2409. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.The drug has already received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration.<h2 class="st-heading-2">How Did CADL Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has risen 72% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dal-m-amzn-v-unh-in-focus-as-berkshire-rejigs-portfolio/cZXmfX1Rekg">DAL, M, AMZN, V, And UNH Stocks In Focus As Berkshire Rejigs Portfolio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data  

The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo. 

Equity

<ul class="summary-bullets"><li>Candel is set to submit a Biologics License Application to the U.S. Food and Drug Administration by the fourth quarter of 2026.</li><li>The Phase 3 trial, which met its primary endpoint, included 745 patients.</li><li>The company also expects to present additional biomarker data by the third quarter of 2026.</li></ul>Shares of Candel Therapeutics (CADL) climbed 3% higher in pre-market trading on Friday, lifted by growing investor optimism ahead of a closely watched presentation of pivotal follow-up data for its prostate cancer therapy at the American Urological Association (AUA) 2026 Annual Meeting Plenary Program.On Thursday, the biotech firm posted a first-quarter (Q1) loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.<h2 class="st-heading-2">All Eyes On CADL’s Phase 3 Follow-Up Data</h2>Candel is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene (CAN-2409) in patients with localized, intermediate- to high-risk prostate cancer, and also announced plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the treatment by the fourth quarter of 2026.A BLA is a formal request to allow for the marketing and sales of a therapy in the United States.In the third quarter of 2026, the company expects to present additional biomarker data. The drug has already been granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations by the U.S. Food and Drug Administration (FDA).<h2 class="st-heading-2">What Did Phase 3 Results Show?</h2>In December 2024, Candel reported positive Phase 3 results for its CAN-2409 therapy. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.The trial was randomized, double-blind, placebo-controlled, and included 745 patients. The goal was to improve disease-free survival in patients with intermediate- to high-risk localized prostate cancer.<h2 class="st-heading-2">Retail’s Take On CADL’s Presentation</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CADL">CADL</a> on Stocktwits remained in the ‘bullish’ zone, while message volumes on the platform surged more than 130% over a 24-hour period.One user expects the readout to be “significant,” as it could show a lower hazard ratio and potentially speed up the drug’s approval process.<stembedurl>https://stocktwits.com/drizz/message/653381214</stembedurl>Another user said that regardless of Friday’s outcome, the company’s market capitalization could more than double by the time Candel submits its BLA, potentially paving the way for a future acquisition.<stembedurl>https://stocktwits.com/drizz/message/653477842</stembedurl>CADL shares have gained around 50% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of stock market chart on a glowing particle world map. BRUN shares rallied 38% this week. (Representative Image: Getty Images)

CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches

Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer

CADL Stock Is Surging Again – And Retail Traders Are Watching Friday’s Cancer Data Closely 

<ul class="summary-bullets"><li>The company posted a loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.</li><li>Candel will present its follow-up data at the American Urological Association 2026 annual meeting plenary program on Friday.</li><li>The biotech firm is set to begin a Phase 3 trial for lung cancer treatment in June.</li></ul>Candel Therapeutics (CADL) was in the spotlight on Thursday as investors turned their attention away from the company’s first-quarter earnings toward a highly anticipated follow-up data readout from its pivotal Phase 3 prostate cancer trial.Candel will present the data at the American Urological Association (AUA) 2026 annual meeting plenary program on Friday.<a href="https://stocktwits.com/symbol/CADL">CADL shares</a> were trading around 2% lower at the time of writing.<h2 class="st-heading-2">CADL’s Prostate Cancer Therapy In Focus</h2>In December 2024, Candel announced positive Phase 3 trial results for its CAN-2409 cancer therapy in patients with localized prostate cancer. The study met its primary goal, showing that patients who received CAN-2409 in addition to standard treatment remained disease-free longer than those who received standard treatment alone.The drug has already received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration (FDA), and Candel now plans to complete manufacturing process validation in the second quarter to support a planned Biologics License Application (BLA) submission in Q4 2026.<h2 class="st-heading-2">CADL To Begin Phase 3 Trial For Lung Cancer Treatment In June</h2>Candel recently reported updated long-term data from a Phase 2 trial studying CAN-2409 in advanced non-small cell lung cancer (NSCLC) patients who had not responded well to prior immunotherapy treatment.Half of the 46 patients in the study survived for more than 24 months despite having difficult-to-treat disease and poor prognostic factors. Median overall survival ranged from 21.5 to 25.4 months across different patient groups. The company plans to begin a Phase 3 trial in June 2026.Separately, the company posted a loss of $0.14 per share, compared to consensus estimates of a loss of $0.33 per share, according to Fiscal.ai data.<h2 class="st-heading-2">CADL Bulls Bet On Positive Data</h2>Retail sentiment trended in the ‘bullish’ territory on Stocktwits, while message volumes remained ‘high’ over a 24-hour period.One user said if the follow-up data readout is positive, the stock could run past $12. It is currently trading at around $9.<stembedurl>https://stocktwits.com/haha1978/message/653346180</stembedurl>Another user expects Friday to be “epic” for the company.<stembedurl>https://stocktwits.com/drizz/message/653351186</stembedurl>The stock has gained around 47% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-surge-q1-results-defencath-sales/cZX1AAmRe1t">CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow 

Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High  - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...

Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...

Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...

UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline

(RTTNews) - United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases...

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.read more...

Candel Therapeutics (NASDAQ:CADL) Sees Large Volume Increase - Time to Buy?

Candel Therapeutics (NASDAQ:CADL) Sees Unusually-High Trading Volume - Should You Buy...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Experts and investors are buzzing about the therapeutic potential, comparing its impact and adoption path to the legendary cancer treatment Keytruda.

With a high-conviction clinical signal and robust insider backing, market participants are aggressively positioning for a potential multibillion-dollar acquisition.

Bulls are doubling down, labeling recent price dips as intentional 'shake outs' while highlighting a very tight float that could trap over-leveraged shorts.

Recent Phase 3 data presentations at AUA revealed significant improvements in recurrence-free survival, cementing the therapy as a potential new standard of care.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest CADL News

CADLCandel Therapeutics Inc